Article
Health Care Sciences & Services
Wojciech A. Cieslikowski, Piotr Milecki, Monika Swierczewska, Agnieszka Ida, Michal Kasperczak, Agnieszka Jankowiak, Michal Nowicki, Klaus Pantel, Catherine Alix-Panabieres, Maciej Zabel, Andrzej Antczak, Joanna Budna-Tukan
Summary: The aim of this study was to determine if baseline circulating tumor cell (CTC) count could predict overall survival (OS) and metastasis-free survival (MFS) in high-risk prostate cancer (PCa) patients during a follow-up of 5 years or more. Three different assay formats were used to enumerate CTCs in 104 patients, including the CellSearch((R)) system, EPISPOT assay, and GILUPI CellCollector. The results showed that a baseline CTC count of >=1, determined by the CellSearch((R)) system, Gleason sum >=8, cT >=2c, and initial diagnosis with metastases were significant predictors of worse OS in the entire cohort. In a subset of 85 patients with localized PCa at baseline, only baseline CTC count of >=1 was a significant predictor of worse OS. The MFS was not affected by the baseline CTC number. In conclusion, baseline CTC count can be considered a determinant of survival in high-risk PCa and patients with localized disease. However, longitudinal monitoring is necessary to fully understand the prognostic value of CTC count in localized PCa.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Urology & Nephrology
Andreas G. Wibmer, Joshua Chaim, Yulia Lakhman, Robert A. Lefkowitz, Josip Nincevic, Ines Nikolovski, Evis Sala, Mithat Gonen, Sigrid V. Carlsson, Samson W. Fine, Michael J. Zelefsky, Peter Scardino, Hedvig Hricak, Hebert Alberto Vargask
Summary: T2-weighted magnetic resonance imaging findings in localized prostate cancer patients are associated with long-term oncologic outcomes. Combining MRI results with clinical risk markers improves prognostication accuracy for metastases and prostate cancer death.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Ruth Pidsley, Dilys Lam, Wenjia Qu, Timothy J. Peters, Phuc-Loi Luu, Darren Korbie, Clare Stirzaker, Roger J. Daly, Phillip Stricker, James G. Kench, Lisa G. Horvath, Susan J. Clark
Summary: This study used methylome sequencing to investigate the DNA methylation patterns in prostate cancer patients, and identified methylation patterns associated with prostate cancer-specific mortality, as well as prognostic biomarkers. The combination of DNA methylation biomarkers and clinicopathological measures improved the prognostic models for prostate cancer mortality.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Article
Urology & Nephrology
Mark N. Brook, Holly Ni Raghallaigh, Koveela Govindasami, Tokhir Dadaev, Reshma Rageevakumar, Diana Keating, Nafisa Hussain, Andrea Osborne, Artitaya Lophatananon, Kenneth R. Muir, Zsofia Kote-Jarai, Rosalind A. Eeles
Summary: A family history of prostate cancer is associated with an increased risk of developing the disease. This study examines how the number, degree, and age of relatives with prostate cancer are related to overall survival and prostate cancer-specific survival in prostate cancer patients.
Article
Oncology
Yuan Zhou, Changming Lin, Lian Zhu, Rentao Zhang, Lei Cheng, Yuanyuan Chang
Summary: This study established predictive models and a scoring system to predict the survival rate of prostate cancer patients. These tools can help clinicians individually assess the survival status of patients and contribute to clinical decisions.
Article
Medicine, Research & Experimental
Ran Zhang, Feng Liu
Summary: This study established CAF gene signatures that accurately predict the prognosis of prostate cancer patients undergoing radiotherapy.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Frantisek Zitricky, Asta Foersti, Akseli Hemminki, Otto Hemminki, Kari Hemminki
Summary: This study analyzed survival trends in prostate cancer patients in Denmark, Finland, Norway, and Sweden, and found that despite improvements in survival due to PSA testing, changes in clinical presentation have made it difficult to interpret the underlying causes. Further attention is needed to improve prostate cancer survival.
Article
Oncology
Pengfei Guo, Tianhong Teng, Wuping Liu, Yanying Fang, Binbin Wei, Jianghua Feng, Heguang Huang
Summary: Pancreatic ductal adenocarcinoma (PDAC) is highly heterogeneous and clinical stages are not associated with metabolic differences. Through serum metabolomic analysis, three metabolic subtypes were identified, with choline-like type showing better long-term prognosis.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Cell Biology
Zhenfeng Shi, Chutian Xiao, Tengceng Li, Jieying Wu, Ke Li
Summary: The study suggests that high expression of BZW1 in prostate cancer is associated with tumor progression and poor prognosis, promoting cell proliferation by regulating the TGF-beta 1/Smad pathway.
Article
Oncology
Xiang Liu, Wangli Mei, Liang Jin, Xianchao Sun, Zhen Zhou, Shiyong Xin, Liqun Huang, Guosheng Yang, Jinyou Wang, Lin Ye
Summary: A prognostic prediction model for prostate cancer (Pca) based on ubiquitin-related long noncoding ribonucleic acids (lncRNAs) was established. It was found that ubiquitin-related lncRNAs could effectively predict the prognosis of Pca and may offer new treatment options.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Zhuo Huang, Ying Tang, Yuyan Wei, Jingyu Qian, Yifan Kang, Duohao Wang, Miao Xu, Ling Nie, Xueqin Chen, Ni Chen, Qiao Zhou
Summary: Neuroendocrine differentiation (NED) characterized by the expression of neuroendocrine markers, such as chromogranin A (CgA), is frequently observed in advanced prostate cancer (PCa), the prognostic significance of which is still controversial. The study found that CgA expression was an independent adverse prognostic factor for both metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC).
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Yujie Xie, Yongqing Deng, Suosu Wei, Zhen Huang, Lihui Li, Kai Huang, Chunyu Wei, Jinan Xu, Lingguang Dong, Qiuhuan Zhang, Jiehua Zhao, Quanqing Zou, Jianrong Yang
Summary: This study found a U-shaped association between age at diagnosis and breast cancer outcome, with higher risk for both younger and older patients. This is important for understanding the survival, breast cancer-specific survival, and disease-free survival of breast cancer patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Public, Environmental & Occupational Health
Andri Wilberg Orrason, Hans Garmo, Johan Styrke, Paul W. Dickman, Par Stattin
Summary: Net survival, measured in different frameworks, such as relative survival and cause-specific survival, was compared in men with prostate cancer. The study found biases in estimates of survival rates for different age groups and risk categories, emphasizing the importance of evaluating underlying assumptions for each method.
AMERICAN JOURNAL OF EPIDEMIOLOGY
(2021)
Review
Endocrinology & Metabolism
Kechong Zhou, Chao Li, Tao Chen, Xuejun Zhang, Baoluo Ma
Summary: In this meta-analysis of 16 studies, elevated levels of C-reactive protein (CRP) were found to be associated with worse overall survival, cancer-specific survival, and progression-free survival in patients with prostate cancer. Subgroup analysis based on disease staging yielded consistent results. However, further studies are needed to confirm these findings.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Gilles Houvenaeghel, Alexandre de Nonneville, Guillaume Blache, Max Buttarelli, Camille Jauffret, Djamel Mokart, Laura Sabiani
Summary: This study retrospectively analyzed the surgical outcomes and survival of 90 ovarian cancer patients who underwent posterior pelvic exenteration (PPE). The majority of patients achieved complete resection with a low rate of complications. Survival outcomes were associated with the completeness of surgery, chemotherapy cycles, and patient age.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2022)